• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

司库奇尤单抗相关新发炎症性肠病

Ixekizumab Associated New-Onset Inflammatory Bowel Disease.

作者信息

Nazarian Amir, Grin Andrea, Wijeratne Don Thiwanka

机构信息

Department of Medicine, Queen's University, Kingston, Ontario, Canada.

Department of Pathology, Queen's University, Kingston, Ontario, Canada.

出版信息

ACG Case Rep J. 2020 Mar 2;7(2):e00316. doi: 10.14309/crj.0000000000000316. eCollection 2020 Feb.

DOI:10.14309/crj.0000000000000316
PMID:32440523
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7209798/
Abstract

Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.

摘要

司库奇尤单抗是一种靶向白细胞介素-17的单克隆抗体，已被批准用于治疗银屑病。在最近一项针对抗白细胞介素-17药物治疗斑块状银屑病的I期至III期临床试验的事后荟萃分析中，发现与炎症性肠病的诱发或加重存在罕见关联（<1%）。我们报告了一例48岁女性患者，其因银屑病正在使用司库奇尤单抗治疗，却新发了回肠克罗恩病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fce/7209798/99a302d6d636/ac9-7-e00316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fce/7209798/b1498fd46d03/ac9-7-e00316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fce/7209798/99a302d6d636/ac9-7-e00316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fce/7209798/b1498fd46d03/ac9-7-e00316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fce/7209798/99a302d6d636/ac9-7-e00316-g002.jpg

相似文献

1
Ixekizumab Associated New-Onset Inflammatory Bowel Disease.司库奇尤单抗相关新发炎症性肠病
ACG Case Rep J. 2020 Mar 2;7(2):e00316. doi: 10.14309/crj.0000000000000316. eCollection 2020 Feb.
2
Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.抗白细胞介素-17 阻断剂（依奇珠单抗）治疗慢性斑块状银屑病致克罗恩样疾病 1 例报告。
BMC Gastroenterol. 2019 Sep 5;19(1):162. doi: 10.1186/s12876-019-1067-0.
3
Ustekinumab as a Treatment for Ixekizumab-Associated New-Onset Crohn's Disease in a Patient with Psoriasis.乌司奴单抗治疗一名银屑病患者中与司库奇尤单抗相关的新发克罗恩病
ACG Case Rep J. 2024 Jan 31;11(2):e01266. doi: 10.14309/crj.0000000000001266. eCollection 2024 Feb.
4
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.接受依奇珠单抗治疗的银屑病患者中的炎症性肠病：来自 7 项随机对照和非对照试验综合数据库的已裁定数据报告。
J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24.
5
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.白细胞介素-17抑制：在银屑病和炎症性肠病中的作用。
J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31.
6
Severe de novo Ulcerative Colitis following Ixekizumab Therapy.司库奇尤单抗治疗后出现严重的新发溃疡性结肠炎。
Case Rep Gastroenterol. 2018 Oct 17;12(3):617-621. doi: 10.1159/000493922. eCollection 2018 Sep-Dec.
7
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).在依那西普无反应者中转换为司库奇尤单抗的疗效和安全性：来自两项中重度斑块状银屑病III期随机临床试验（UNCOVER-2和-3）的亚组分析
Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.
8
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.依奇珠单抗治疗中重度斑块状银屑病：NICE 单技术评估的循证评估组观点。
Pharmacoeconomics. 2018 Aug;36(8):917-927. doi: 10.1007/s40273-018-0629-2.
9
Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.依奇珠单抗：用于治疗中度至重度斑块型银屑病的研究进展。
Ann Pharmacother. 2019 Mar;53(3):276-284. doi: 10.1177/1060028018799982. Epub 2018 Sep 6.
10
Ixekizumab for the treatment of psoriasis: an update on new data since first approval.依奇珠单抗治疗银屑病：首次批准以来新数据的更新。
Expert Rev Clin Immunol. 2019 Feb;15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27.

引用本文的文献

1
Drug-induced entero-colitis due to interleukin-17 inhibitor use; capsule endoscopic findings and pathological characteristics: A case report.药物性肠-结肠炎与白细胞介素-17 抑制剂的使用有关：胶囊内镜检查结果和病理特征：一例报告。
World J Gastroenterol. 2023 Aug 28;29(32):4912-4919. doi: 10.3748/wjg.v29.i32.4912.
2
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.银屑病患者炎症性肠病与白细胞介素-17抑制剂生物治疗之间可能关联的见解。
Pharmaceutics. 2023 Aug 21;15(8):2171. doi: 10.3390/pharmaceutics15082171.
3
New-Onset Crohn's Disease following Initiation of Secukinumab: A Case Report and Review of the Role of IL-17 in the Pathogenesis of Crohn's Disease.

本文引用的文献

1
Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.系统评价与荟萃分析：抗白细胞介素-17 药物治疗的新发炎症性肠病风险。
Aliment Pharmacol Ther. 2019 Aug;50(4):373-385. doi: 10.1111/apt.15397. Epub 2019 Jul 15.
2
Severe de novo Ulcerative Colitis following Ixekizumab Therapy.司库奇尤单抗治疗后出现严重的新发溃疡性结肠炎。
Case Rep Gastroenterol. 2018 Oct 17;12(3):617-621. doi: 10.1159/000493922. eCollection 2018 Sep-Dec.
3
New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.
司库奇尤单抗治疗后新发克罗恩病：一例报告及IL-17在克罗恩病发病机制中的作用综述
Case Rep Gastrointest Med. 2023 May 22;2023:1769290. doi: 10.1155/2023/1769290. eCollection 2023.
4
IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis.白细胞介素-17抑制剂相关的炎症性肠病：一项基于文献和数据库分析的研究
Front Pharmacol. 2023 Mar 23;14:1124628. doi: 10.3389/fphar.2023.1124628. eCollection 2023.
5
Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?银屑病患者对抗肿瘤坏死因子α和抗白细胞介素-17治疗的矛盾反应：皮肤和/或肠道微生物群是否参与其中？
Dermatol Ther (Heidelb). 2023 Apr;13(4):911-933. doi: 10.1007/s13555-023-00904-4. Epub 2023 Mar 15.
6
Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis.在使用依奇珠单抗治疗慢性斑块状银屑病的情况下，出现严重的药物相关性结肠炎，具有克罗恩病特征。
BMC Gastroenterol. 2021 Oct 2;21(1):361. doi: 10.1186/s12876-021-01936-w.
3例接受白细胞介素-17A抑制剂司库奇尤单抗治疗的患者新发炎症性肠病：病例系列
Am J Gastroenterol. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z.
4
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.接受司库奇尤单抗输注后炎症性肠病的快速发作。
ACG Case Rep J. 2018 Aug 1;5:e56. doi: 10.14309/crj.2018.56. eCollection 2018.
5
Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.在使用司库奇尤单抗治疗期间出现炎症性肠病。
J Crohns Colitis. 2018 Aug 29;12(9):1131-1133. doi: 10.1093/ecco-jcc/jjy063.
6
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.一项关于布罗达单抗治疗中度至重度克罗恩病患者的随机、双盲、安慰剂对照2期研究。
Am J Gastroenterol. 2016 Nov;111(11):1599-1607. doi: 10.1038/ajg.2016.298. Epub 2016 Aug 2.
7
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.依奇珠单抗治疗中重度斑块状银屑病的 3 期临床试验。
N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.
8
Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.辅助性T细胞17作为炎症性肠病潜在的益生菌治疗靶点
Int J Mol Sci. 2015 Sep 1;16(9):20841-58. doi: 10.3390/ijms160920841.
9
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
10
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.司库奇尤单抗，一种人源抗白细胞介素-17A 单克隆抗体，用于中重度克罗恩病：一项随机、双盲、安慰剂对照试验的意外结果。
Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.